Professor Hans-Dirk Duengen
Scirent - Clinical Research and Science, Berlin (Germany)
Membership:
FESC Member
HFA Member
Biography
Dr. Hans-Dirk Düngen is an accomplished physician at Charité University Hospital Berlin and co-founder of SCIRENT, a full-service contract research organization (CRO).
As a senior cardiologist at Charité University Hospital Berlin, he specializes in treating patients with heart failure and has collected a wealth of national and international experience in initiating and executing clinical trials. Also, he is the author of numerous scientific publications.
He co-founded SCIRENT in 2012 with the vision to help clients develop innovative medical drugs and devices for patients with cardiovascular diseases. As the CEO of this company, he and his dedicated team of experienced clinical and regulatory professionals provide faster and more efficient clinical trial services in Europe and North America.
Contributor content
Presentation
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodelling after acute myocardial infarction - Results of the CHIARA MIA 2 trial
Presentation
Reliability of peripheral arterial tonometry for assessment of endothelial function in patients with heart failure with preserved and reduced ejection fraction, diabetic nephropathy and arterial hyper
Presentation
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Preserved Ejection Fraction: Rationale and d
Presentation
Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial
Presentation
Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial
Presentation
Effects of beta-blocker therapy on hs-CRP levels in elderly patients with ischemic and non-ischemic heart failure: Results from the CIBIS-ELD trail
Presentation
Test-retest-reliability of measurement of circulating endothelial and endothelial progenitor cells in peripheral blood in patients with heart failure, diabetic nephropathy and arterial hypertension
Presentation
Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial
Presentation
